Abbott cuts 2021 profit forecast on lower COVID-19 testing demand
Reuters
Published Jun 01, 2021 08:58AM ET
Updated Jun 01, 2021 12:06PM ET
By Dania Nadeem
(Reuters) - Abbott Laboratories (NYSE:ABT) on Tuesday cut its full-year 2021 profit forecast as it expects a sharp decline in revenue from its COVID-19 tests as more Americans get vaccinated, sending the medical device maker's shares down more than 6%.
"This has been driven by several factors, including significant reductions in (COVID-19) cases in the U.S. and other major developed countries, accelerated roll-out of vaccines globally and, most recently, U.S. health authority guidance on testing for fully vaccinated individuals," the company said.
The new guidance from the Centers for Disease Control and Prevention issued in May allows people who have been vaccinated to travel in the U.S. without getting tested before or after travel. (https://
Abbott got more than $3 billion from sales of its COVID-19 tests last year, but analysts have cautioned that demand is likely to fall this year.
Rivals Quest Diagnostics (NYSE:DGX) Inc and Becton, Dickinson and Co said over the last couple of months that demand for COVID-19 tests has started to decelerate and expect lower sales in the coming quarters.
Abbott, which generated half of its total COVID-19 testing sales in the first quarter from overseas markets, said it expects a similar drop in testing demand in international markets.
"We'll start to see that (drop in testing demand) first with the developed markets as the vaccination rates in those increase and accelerate," Chief Executive Officer Robert Ford said.
The company forecast 2021 sales related to COVID-19 testing between $4.0 billion and $4.5 billion, compared with its prior outlook of $6.5 billion to $7.0 billion.
The company now expects full-year adjusted profit from continuing operations of $4.30 to $4.50 per share, compared with its prior forecast at least $5 per share in January. Analysts expect the company to earn $5.04 per share, according to Refinitiv IBES data.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.